ABL Diagnostics Proposes Acquisition to Expand Global Reach

ABL Diagnostics, in collaboration with its parent company Advanced Biological Laboratories, has signed a non-binding letter of intent to acquire Vela Operations Singapore and Vela Diagnostics USA. This strategic move aims to bolster ABL's international presence, spanning EMEA, Asia-Pacific, and the United States. The acquisition aligns with ABL's previous exclusive distribution agreement with Vela Diagnostics in EMEA.

The completion of the acquisition is subject to several conditions, including successful due diligence and regulatory approvals. If finalized, the acquisition will not alter the control or governance of ABL Texcell Diagnostics or its parent, Advanced Biological Laboratories.

Dr. Chalom Sayada, CEO of ABL Texcell Diagnostics, emphasized the acquisition's potential to strengthen the company's capabilities and reinforce its position in the molecular diagnostics market for infectious diseases.